OriCell Therapeutics
Aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | $45.0m Valuation: $600m | Series B | |
| Total Funding | 000k | ||
Related Content
OriCell Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of cell therapies for cancer treatment. The company has established a proprietary technology platform, OriCAR, which is designed to enhance the effectiveness of Chimeric Antigen Receptor T-cell (CAR-T) therapies.
Their primary focus is on addressing unmet medical needs in oncology, particularly for solid tumors and hematological malignancies. OriCell's pipeline includes several investigational CAR-T therapies. One of their leading candidates, OriCAR-017, targets GPRC5D for the treatment of relapsed and refractory multiple myeloma. This therapy has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), indicating its potential to address a serious condition.
The company operates internationally, with a presence in both China and the United States, allowing it to conduct clinical trials and navigate regulatory processes in multiple key markets. OriCell's business model is centered on the research and development of these advanced therapies, with the ultimate goal of commercializing them to provide new treatment options for cancer patients.
Keywords: CAR-T therapy, oncology, cell therapy, multiple myeloma, solid tumors, biopharmaceutical, clinical-stage, GPRC5D, OriCAR platform, cancer immunotherapy